The PTEN deletion was also reported in 15% of poorly differentiated serous ovarian cancers (94), and Pten mutations were also found in 20% of endometrioid ovarian cancers (95); approximately 53% of patients with primary bladder cancer showed a decrease or deletion of the Pten protein in the cytoplasm or nucleus of their tumor cells (96). The gene discussed is PTEN; the disease is ovarian serous adenocarcinoma.